Solid Biosciences Inc

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Sales of Unregistered Securities

Except as set forth below, we did not sell any securities during the three months ended March 31, 2025 that were not registered under the Securities Act of 1933, as amended (the "Securities Act"), and that have not otherwise been described in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.

Following the FDA's clearance of our IND application for SGT-212 for the treatment of FA, a $5.0 million development milestone became payable to FA212. On February 28, 2025, we made the first milestone payment in the form of 975,496 shares of our common stock. For more information about this agreement, see Note 2 -FA212 Asset Acquisition. The shares were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act as a privately negotiated transaction not involving any public offer or solicitation. On March 6, 2025, we filed a registration statement covering the resale of the shares of common stock issued to FA212, which was declared effective on March 14, 2025. None of the shares were sold through an underwriter and accordingly, there were no underwriting discounts or commissions involved.